The era of next-generation sequencing (NGS) has led to a deeper understanding of the genetic complexity and heterogeneity of this disease, in addition to revealing mechanisms of disease relapse. Clinical NGS is becoming routine in clinical practice in both solid organ and hematologic malignancies to identify molecular markers of disease that might assist with diagnosis, prognosis, and the treatment of cancer. These tumor-specific markers also enable treatment response monitoring, as they serve as clonal markers unique to the disease. Continuous molecular monitoring also allows identification of disease recurrence with potentially new actionable mutations. This practice is complicated in the setting of allogeneic bone marrow transplant, as the admixtures of donor and recipient DNA pose unique challenges to NGS interpretation. This case highlights the importance of systematic methodological interpretation of NGS results to better understand the clinical significance and impact of new mutations discovered posttransplant and reveals another potential application of NGS for bone marrow engraftment analysis.
From the *Department of Medicine, University of California, Los Angeles, Los Angeles, CA
†Department of Pathology, University of Rochester, Rochester, NY
‡Department of Pathology, Knight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR
§Department of Pathology & Lab Medicine, University of California, Los Angeles, Los Angeles, CA
∥Department of Pathology and Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD.
Reprints: Rena R. Xian, MD, Johns Hopkins Genomics, 1812 Ashland Ave, Suite 200, Baltimore, MD 21205. E-mail: email@example.com.
M.J.K. and G.M.C. contributed equally to this work.
The authors have no funding or conflicts to declare.